Pre-announcement: Call to advance research on AMR transmission

With an estimated total budget of €28 million, the EUP OHAMR Joint Transnational Call 2027 will bring together 33 funding organisations from 26 countries to support international research collaborations aimed at improving our understanding of antimicrobial resistance (AMR) transmission and developing effective strategies to prevent its emergence and spread across the One Health spectrum.

We are pleased to pre-announce the Joint Transnational Call (JTC) 2027 – Understand, Model and Stop AMR Transmission, which will open on 18 November 2026. The call is co-funded by the European Union.

The call will focus on preventing the emergence and spread of antimicrobial resistance (AMR), one of the most pressing global health challenges affecting humans, animals and the environment. Although significant efforts have been made and new technologies have emerged, current approaches remain insufficient to reduce the burden of AMR. A deeper understanding of transmission dynamics is essential to strengthen prevention and control strategies.

Novel and improved measures are urgently required to tackle AMR more effectively, informed by a deeper understanding of the mechanisms driving the emergence, evolution, selection, persistence and transmission of resistance within and between the One Health sectors. To address these challenges, the JTC 2027 will fund transnational research projects within the following topics:

Topic 1

Model AMR transmission dynamics to predict the risk of AMR emergence and spread to support decision-making of public authorities.

Topic 2

Understand and characterise the role of host commensal micro-organisms (including fungi) in AMR dynamics and develop solutions aiming at selective decolonising of resistant organisms in the host (human and animals) to prevent transmission.

Topic 3

Develop or improve tools and methods to reduce resistant bacteria, fungi, and resistance genes in environmental hotspots, and investigate the impact of these tools and methods on AMR transmission.

Participating countries and funding organisations

Please note that there may be changes to the list of participating countries and funding organisations below, and that details regarding national eligibility rules will not be published before the call opens.

• Australia – National Health and Medical Research Council (NHMRC)
• Austria – Fonds zur Förderung der Wissenschaftlichen Forschung (FWF)
• Belgium – Fonds de la Recherche Scientifique (FNRS)
• Belgium – Service Public de Wallonie (SPW)
• Canada – Canadian Institutes of Health Research (CIHR)
• Czech Republic – Ministerstvo Zdravotnictvi Ceske Republiky (MZCR)/ Agentura pro zdravotnicky vyzkum (AZVCR)
• Denmark – Innovationsfonden, Innovation Fund Denmark (IFD)
• Estonia – Regionaal- ja Põllumajandusministeerium (REM)
• France – Agence Nationale de la Recherche (ANR)
• Germany – Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
• Germany – Deutsches Zentrum für Luft- und Raumfahrt Projektträger (DLR-PT)
• Hungary – Nemzeti Kutatási, Fejlesztési Innovációs Hivatal (NKFIH)
• Ireland – Department of Agriculture, Food and the Marine (DAFM)
• Ireland – Taighde Éireann – Research Ireland (TÉ-RI)
• Ireland – The Health Research Board (HRB)
• Israel – Ministry Of Health – Chief Scientist Office (CSO-MOH)
• Italy – Ministero della Salute (MOH-IT)
• Latvia – Latvijas Zinatnes Padome (LZP)
• Lithuania – Lietuvos Mokslo Taryba (LMT)
• Malta – Xjenza Malta (XM)
• Moldova – National Agency for Research and Development (NARD)
• Netherlands – Zorgonderzoek Nederland (ZonMw)
• Norway – The Research Council of Norway (RCN)
• Poland – Narodowe Centrum Nauki (NCN)
• Slovakia – Centrum Vedecko Technickych Informacii Slovenskej Republiky (CVTI SR)
• Spain – Instituto de Salud Carlos III (ISCIII)
• Spain – Instituto Aragones de Ciencias de la Salud (IACS)
• Spain – Agencia Estatal de Investigación (AEI)
• Sweden – Vetenskapsrådet, Swedish Research Council (SRC)
• Switzerland – Schweizerischer Nationalfonds zür Forderung der Wissenschaftlichen Forschung (SNSF)
• Türkiye – Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
• United Kingdom – Medical Research Council – United Kingdom Research and Innovation (MRC – UKRI)
• United Kingdom – Department of Health and Social Care (DHSC)

Who can apply?

The call will only support transnational research and innovation projects and will follow a two-step evaluation process.

To be eligible for funding, project consortia must meet the following requirements regarding their composition:

• A minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
• A maximum of six (6) project partners (including non-funded partners).
• The maximum number of partners can be increased to seven (7) if the consortium includes:
  • at least one partner from an under-represented country,
  • at least one partner where the Principal Investigator meets the definition of an Early-Career Researcher or,
  • a start-up, SME, or an Industry.
• A consortium cannot include more than two (2) partners requesting funding from the same funding organisation.
• A principal investigator can apply for maximum two proposals, one as partner and one as coordinator (and in accordance to national/regional funding eligibility rules).

For the purpose of this call, the under-represented countries are: Czech Republic, Hungary, Latvia, Lithuania, Malta, Moldova, Poland, and Slovakia.

An online partner search tool will be available when the call opens.

Webinar for applicants

On 25 November, we will be organising a webinar for applicants interested in the EUP OHAMR JTC 2027 

During the webinar, we will present the call and demonstrate the partner search tool. Representatives from funders participating in the call will also be available to answer questions, such as:

• What is the EUP OHAMR, and how can I find out if I am eligible for funding?
• How can I find and create research collaborations?
• How do I apply, and how does the funding work?

open_in_new

Registration

Link to another website

Register to the webinar through our event platform Invajo.

Potential topics for the EUP OHAMR joint transnational call 2027

The second EUP OHAMR joint transnational call will be within the focus area of preventing the emergence and spread of AMR. We are now sharing a list of call topics that are currently under consideration.

The call is still under development, but it is now clear that it will include one or more of the topics listed below.

Please note that the exact wording may change, and the definition of the call topic(s) may be further refined. The final list of selected topics will be published in October, together with an indicative list of the countries participating in the call.

The EUP OHAMR joint transnational call 2027 will be launched in November 2026.

Potential call topics

• Identify the reservoirs of AMR genes carried by mobile elements in different One-Health contexts, quantify the magnitude of transfer, and/ or inhibit their diffusion.
• Explore how changing environments (e.g. climate change, pollution) drive AMR resistance emergence, spread, ecology and evolution across bacterial and fungal pathogens.
• Model AMR transmission dynamics to predict the risk of AMR emergence and spread to support decision making of public authorities.
• Understand and strengthen awareness of AMR transmission routes across One Health sectors and especially in vulnerable groups.
• Understand and characterize the role of host commensal micro-organisms (including fungi) in AMR dynamics and develop solutions aiming at decolonizing the host (human and animals) to prevent transmission.
• Identify the environmental microbiota present in soil, water, air, wildlife, pests and rodents as a source of emergence of novel AMR, AMR spread and reservoir of clinically relevant AMR. 
• Unravel the drivers of emergence/ re-emergence and spread of resistant bacteria in difficult or extreme situations (e.g. natural disasters/wars), and formulate effective strategies for mitigation.
• Identify risks and potential solutions to limit AMR in circular economy.
• Understand the drivers (including the socio-economic ones) of antibacterial and antifungal resistance in food systems and develop solutions.
• Develop or improve tools and methods to facilitate the reduction of resistant bacteria and fungi and resistance genes in environmental hotspots and investigate the impact on these tools and methods on AMR Transmission.

Research call on new treatments to tackle AMR now open

The first EUP OHAMR joint transnational call "Treatments and adherence to treatment protocols" is now open! The call involves 37 funding organisations from 28 different countries and has an estimated total call budget of over 31 million Euro. The call is co-funded by the European Union.

Drug-resistant infections are responsible for an increasing number of treatment failures, increased mortality and decreased food productivity. Inappropriate use, poor adherence to prescriptions, and overuse of antibiotics are one of the main drivers of AMR and have a detrimental impact on the effectiveness of these critical medicines.

To develop novel treatment protocols or alternative treatment strategies against infectious diseases and to improve, preserve and reinforce the clinical efficacy of the current treatment antimicrobials is vital. It is also necessary to identify barriers preventing the proper adherence of the end-users to the treatment protocols already in place.

This first EUP OHAMR Call aims to improve the treatment success rates of the patients/animals/plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance in the different One Health settings.

Pre-announcement: Research call on new treatments to tackle AMR

We are pleased to pre‐announce the first EUP OHAMR joint transnational call "Treatments and adherence to treatment protocols" which will explore new treatments to tackle AMR. The call involves 36 funding organisations from 28 different countries and has an estimated total call budget of over 28 million Euro.

Drug-resistant infections are responsible for an increasing number of treatment failures, increased mortality and decreased food productivity. Inappropriate use, poor adherence to prescriptions, and overuse of antibiotics are one of the main drivers of AMR and have a detrimental impact on the effectiveness of these critical medicines. To develop novel treatment protocols or alternative treatment strategies against infectious diseases and to improve, preserve and reinforce the clinical efficacy of the current treatment antimicrobials is vital. It is also necessary to identify barriers preventing the proper adherence of the end-users to the treatment protocols already in place.

This first EUP OHAMR Call aims to improve the treatment success rates of the patients/animals/plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance in the different One Health settings.

The call, co-funded by the European Union, opens on 18 November 2025.